BRCA1 and neoplasm: In the case of PARPi, the ability to activate immune responses directly correlates with their anti‐tumour activity, as highlighted in pre‐clinical models of BRCA1‐deficient ovarian (Huang et al, 2015; Ding et al, 2018) and triple negative breast tumours (Pantelidou et al, 2019).